# A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

> **NCT06483334** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 38 (estimated)

## Conditions studied

- Metastatic Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** Sacituzumab tirumotecan
- **BIOLOGICAL:** Enfortumab Vedotin
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Supportive care measures

## Key facts

- **NCT ID:** NCT06483334
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06483334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06483334, "A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06483334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*